In a report released today, Joseph Stringer from Needham maintained a Hold rating on Moderna (MRNA – Research Report). The company's shares closed last Tuesday at $142.28, close to its 52-week low of $119.01. According to TipRanks.com, Stringer has 0 stars on 0-5 stars ranking scale with an average return of -25.4% and a 24.7% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Apellis Pharmaceuticals, and Phathom Pharmaceuticals. Moderna has an analyst consensus of Moderate Buy, with a price target consensus of $237.20, implying a 72.5% upside from current levels.
https://www.tipranks.com/news/blurbs/needham-sticks-to-their-hold-rating-for-moderna-mrna?utm_source=advfn.com&utm_medium=referral
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Jun 2022 até Jul 2022 Click aqui para mais gráficos Moderna.
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Jul 2021 até Jul 2022 Click aqui para mais gráficos Moderna.